These disappointing results may be explained in part by pre-clinical and phase I data that have suggested potential loss of negative feedback regulation over Akt, derived from the use of mTOR inhibitors alone or combined with standard chemoradiotherapy in the treatment of high grade glioma. Here, AKT1 is linked to central nervous system cancer.